We are live on ! Find out more
MTNB icon

Matinas BioPharma
MTNB

55 hedge funds and large institutions have $18M invested in Matinas BioPharma in 2022 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 9 increasing their positions, 7 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

125% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 4

29% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 7

10% more funds holding

Funds holding: 50 → 55 (+5)

0.01% more ownership

Funds ownership: 0.25% → 0.26% (+0.01%)

16% less capital invested

Capital invested by funds: $21.5M → $18M (-$3.49M)

Holders
55
Holders Change
+5
Holders Change %
+10%
% of All Funds
0.95%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
9
Reduced
7
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
LPL Financial
LPL Financial
California
+$279K
2
SIG
Sargent Investment Group
Maryland
+$194K
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$109K
4
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$77.8K
5
Renaissance Technologies
Renaissance Technologies
New York
+$26.6K

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$51.7K
2
VF
Virtu Financial
New York
-$51.6K
3
PAG
Private Advisor Group
New Jersey
-$47.1K
4
IIA
IPG Investment Advisors
California
-$45K
5
Jane Street
Jane Street
New York
-$22.9K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$5.36M +$12.6K +322 +0.2%
SIG
2
Sargent Investment Group
Maryland
$2.9M +$194K +4,929 +6%
BlackRock
3
BlackRock
New York
$2.72M -$51.7K -1,317 -2%
NRS
4
Neville Rodie & Shaw
New York
$1.11M – – –
Geode Capital Management
5
Geode Capital Management
Massachusetts
$1.07M +$109K +2,780 +9%
AWA
6
Arkadios Wealth Advisors
Georgia
$890K – – –
JEST
7
JTC Employer Solutions Trustee
Jersey
$508K – – –
BCM
8
Bridgeway Capital Management
Texas
$479K – – –
State Street
9
State Street
Massachusetts
$453K – – –
LPL Financial
10
LPL Financial
California
$394K +$279K +7,099 +134%
SCA
11
STALEY CAPITAL ADVISERS
Pennsylvania
$382K – – –
MSFS
12
Main Street Financial Solutions
Pennsylvania
$255K – – –
Northern Trust
13
Northern Trust
Illinois
$220K +$22.2K +566 +9%
CCM
14
Courage Capital Management
Tennessee
$211K – – –
PAG
15
Private Advisor Group
New Jersey
$109K -$47.1K -1,200 -26%
Bank of New York Mellon
16
Bank of New York Mellon
New York
$106K – – –
PTP
17
Platform Technology Partners
New York
$103K +$15.7K +400 +14%
Jane Street
18
Jane Street
New York
$85K -$22.9K -583 -18%
KCIA
19
Kingsbury Capital Investment Advisors
Illinois
$76K – – –
Balyasny Asset Management
20
Balyasny Asset Management
Illinois
$63K +$77.8K +1,982 New
CDH
21
Charles D. Hyman
$51K – – –
Charles Schwab
22
Charles Schwab
California
$50K – – –
NWMG
23
National Wealth Management Group
Ohio
$29.3K +$1.49K +38 +4%
JP Morgan Chase
24
JP Morgan Chase
New York
$29K – – –
AWS
25
Atria Wealth Solutions
New York
$25.1K – – –
1
2 3

MTNB Hedge Fund Activity: Q3 2022 in Review

55 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Matinas BioPharma (MTNB) for Q3 2022, worth a combined $18M — down 16% from $21.5M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new MTNB positions and 4 closed out — a net gain of 5 holders — while 9 added to existing stakes and 7 trimmed.

The largest buyer was LPL Financial, adding an estimated $279K. The largest seller was BlackRock, cutting an estimated $51.7K.

  • 55 institutional investors held Matinas BioPharma (MTNB) as of Q3 2022, up from 50 in Q2 2022.
  • Funds reported $18M of Matinas BioPharma stock for Q3 2022, down 16% quarter-over-quarter.
  • 9 funds opened new Matinas BioPharma positions in Q3 2022 and 4 closed out, a net change of +5 holders.
  • The largest Matinas BioPharma buyer in Q3 2022 was LPL Financial, an estimated $279K added.
  • The largest Matinas BioPharma seller in Q3 2022 was BlackRock, an estimated $51.7K sold.

Based on aggregated 13F filings for Q3 2022.